Xs 05 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05.

Alzheimer disease cooperativeAxsome therapeutics incDrug administrationDisease cooperativeAssessing clinical outcomesDisease agitationBreakthrough therapyCohen mansfield agitation inventoryOpen label period resultsPhysically aggressiveNasdaq axsmAxsome therapeuticsXs 05D agitationLzheimer 39s disease